Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer

Share :
Published: 24 Oct 2026
Views: 72
Rating:
Save
Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Prof Jens Bedke talks to ecancer at ESMO 2026 about results from the phase III KEYNOTE-866 trial, which evaluated perioperative pembrolizumab alongside neoadjuvant gemcitabine and cisplatin chemotherapy in patients with muscle-invasive bladder cancer (MIBC).

The study randomised 907 patients to receive pembrolizumab or placebo alongside chemotherapy, followed by radical cystectomy and adjuvant treatment.

After a median follow-up of 60.9 months, pembrolizumab did not significantly improve event-free survival (HR 0.88; P = 0.1366) or demonstrate an overall survival benefit (HR 1.00).

Although pathological complete response rates were higher with pembrolizumab (44.4% versus 35.8%), the primary endpoint was not met.

The findings suggest that adding perioperative pembrolizumab to cisplatin-based chemotherapy and surgery does not provide a significant clinical benefit in this patient population.

Related Videos

ESMO 2026: Bladder and kidney cancer roundup

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ESMO 2026: Bladder and kidney cancer roundup ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
2 Nov 2026

ESMO 2026: Prostate cancer roundup

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ESMO 2026: Prostate cancer roundup ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
2 Nov 2026

Outpatient administration of xaluritamig for mCRPC: Feasibility and safety

Prof William Kelly – Thomas Jefferson University, Philadelphia, USA
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety ( Prof William Kelly – Thomas Jefferson University, Philadelphia, USA )
30 Oct 2026

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands
Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
23 Mar 2026

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA

Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA
AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA ( Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA )
18 Mar 2026

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
18 Mar 2026

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA
Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )
17 Mar 2026

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano
ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )
3 Jun 2025

Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer

Dr Fabian Falkenbach - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer ( Dr Fabian Falkenbach - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
1 Apr 2025